Welcome to our dedicated page for Denali Therapeutics news (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeutics stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a leading biotechnology company based in South San Francisco, focused on the discovery and development of breakthrough therapies for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS, as well as lysosomal storage diseases like MPS II (Hunter syndrome) and MPS IIIA (Sanfilippo syndrome Type A).
Founded by a visionary team of scientists, industry experts, and investors, Denali leverages cutting-edge genetic insights and translational medicine tools to address the underlying causes of neurodegeneration. The company is pioneering the use of its proprietary Transport Vehicle (TV) technology, designed to deliver large therapeutic molecules across the blood-brain barrier (BBB) effectively.
Denali’s development pipeline includes several promising programs:
- Tividenofusp alfa (DNL310): An ETV-enabled iduronate-2-sulfatase (IDS) replacement therapy in late-stage development for MPS II.
- DNL343: An eIF2B activator targeting ALS, currently in the Phase 2/3 HEALEY ALS Platform Trial.
- DNL126 (ETV:SGSH): An enzyme replacement therapy for MPS IIIA, selected by the FDA for the START Pilot Program to accelerate rare disease therapeutic development.
- OTV:MAPT: Aiming to treat Alzheimer’s disease by targeting tau proteins.
- BIIB122/DNL151: A LRRK2 inhibitor co-developed with Biogen for Parkinson’s disease.
Denali’s rigorous scientific approach has garnered significant collaborations with industry giants like Sanofi, Takeda, and Biogen, enhancing its potential to revolutionize treatment for these debilitating disorders. Financially, Denali is robust, with over $1.43 billion in cash and marketable securities as of March 31, 2024, and a projected cash runway extending into 2028.
Denali’s latest news includes the initiation of clinical trials for DNL126 and the announcement of program milestones expected to make significant strides in 2024. For more details, visit Denali Therapeutics.
Denali Therapeutics Inc. announced the completion of enrollment for Regimen G in the Phase 2/3 HEALEY ALS Platform Trial, evaluating their eIF2B agonist DNL343. The trial is a collaboration between the Sean M. Healey & AMG Center and the Northeast ALS Consortium. The completion of enrollment marks a significant milestone in the development of DNL343 for the treatment of ALS, with positive feedback from investigators and leaders in the field.
FAQ
What is the current stock price of Denali Therapeutics (DNLI)?
What is the market cap of Denali Therapeutics (DNLI)?
What is Denali Therapeutics Inc. known for?
What are some key products in Denali's pipeline?
What is Denali’s Transport Vehicle (TV) technology?
Who are some of Denali’s key partners?
What is the financial outlook for Denali Therapeutics?
What recent milestones has Denali achieved?
Where is Denali Therapeutics headquartered?
What diseases does Denali focus on?
How does Denali's TV technology work?
What is the significance of Denali’s collaborations?
